BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16890580)

  • 21. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
    N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
    Gurney H; Wong M; Balleine RL; Rivory LP; McLachlan AJ; Hoskins JM; Wilcken N; Clarke CL; Mann GJ; Collins M; Delforce SE; Lynch K; Schran H
    Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
    Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
    Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
    Petain A; Kattygnarath D; Azard J; Chatelut E; Delbaldo C; Geoerger B; Barrois M; Séronie-Vivien S; LeCesne A; Vassal G;
    Clin Cancer Res; 2008 Nov; 14(21):7102-9. PubMed ID: 18981009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.
    McDowell HP; Meco D; Riccardi A; Tanno B; Berardi AC; Raschellà G; Riccardi R; Dominici C
    Int J Cancer; 2007 Mar; 120(5):1141-9. PubMed ID: 17131346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
    Sparreboom A; Gelderblom H; Marsh S; Ahluwalia R; Obach R; Principe P; Twelves C; Verweij J; McLeod HL
    Clin Pharmacol Ther; 2004 Jul; 76(1):38-44. PubMed ID: 15229462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
    Wang L; Giannoudis A; Lane S; Williamson P; Pirmohamed M; Clark RE
    Clin Pharmacol Ther; 2008 Feb; 83(2):258-64. PubMed ID: 17568400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
    Turrini E; Haenisch S; Laechelt S; Diewock T; Bruhn O; Cascorbi I
    Pharmacogenet Genomics; 2012 Mar; 22(3):198-205. PubMed ID: 22241070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
    Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
    Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
    Shukla S; Robey RW; Bates SE; Ambudkar SV
    Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate.
    Oostendorp RL; Marchetti S; Beijnen JH; Mazzanti R; Schellens JH
    Cancer Chemother Pharmacol; 2007 May; 59(6):855-60. PubMed ID: 17180388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms.
    Akamine Y; Sugawara-Kikuchi Y; Uno T; Shimizu T; Miura M
    Ann Clin Biochem; 2017 Nov; 54(6):677-685. PubMed ID: 27932669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs.
    Tamura A; Onishi Y; An R; Koshiba S; Wakabayashi K; Hoshijima K; Priebe W; Yoshida T; Kometani S; Matsubara T; Mikuriya K; Ishikawa T
    Drug Metab Pharmacokinet; 2007 Dec; 22(6):428-40. PubMed ID: 18159130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics of imatinib.
    Peng B; Lloyd P; Schran H
    Clin Pharmacokinet; 2005; 44(9):879-94. PubMed ID: 16122278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
    Chu TS; Chen JS; Lopez JP; Pardo FS; Aguilera J; Ongkeko WM
    Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):979-84. PubMed ID: 18794444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of St John's wort on imatinib mesylate pharmacokinetics.
    Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects.
    Pena MÁ; Muriel J; Saiz-Rodríguez M; Borobia AM; Abad-Santos F; Frías J; Peiró AM
    Clin Drug Investig; 2020 Jul; 40(7):617-628. PubMed ID: 32415468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug transporters and imatinib treatment: implications for clinical practice.
    Eechoute K; Sparreboom A; Burger H; Franke RM; Schiavon G; Verweij J; Loos WJ; Wiemer EA; Mathijssen RH
    Clin Cancer Res; 2011 Feb; 17(3):406-15. PubMed ID: 21163869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.